Biosimilars Market Size & Share – Analysis Report, 2032

Biosimilars Market - By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Hematology, Oncology, Autoimmune Disease, Growth Hormone Deficiency), By Manufacturer, By Technology, Global Forecast, 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Global biosimilars market 360&deg; synopsis, 2018 - 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Product trends

2.1.4&nbsp;&nbsp;&nbsp; Application trends

2.1.5&nbsp;&nbsp;&nbsp; Manufacturer trends

2.1.6&nbsp;&nbsp;&nbsp; Technology trends

Chapter 3&nbsp;&nbsp;&nbsp;Biosimilars Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Strong product pipeline

3.2.1.2&nbsp;&nbsp;&nbsp;Rise in prevalence of chronic diseases across the globe

3.2.1.3&nbsp;&nbsp;&nbsp;Expiry of blockbuster biologics

3.2.1.4&nbsp;&nbsp;&nbsp;Cost-effectiveness of biosimilars

3.2.1.5&nbsp;&nbsp;&nbsp;Recent biosimilar product approvals in major countries

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Availability of alternative medications

3.2.2.2&nbsp;&nbsp;&nbsp;Regulatory uncertainty

3.2.2.3&nbsp;&nbsp;&nbsp;High developmental costs

3.2.2.4&nbsp;&nbsp;&nbsp;Complex manufacturing process

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By product

3.3.2&nbsp;&nbsp;&nbsp; By application

3.3.3&nbsp;&nbsp;&nbsp; By manufacturer

3.3.4&nbsp;&nbsp;&nbsp; By technology

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Technology landscape

3.6&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

3.8&nbsp;&nbsp;&nbsp; Regulatory landscape

3.8.1&nbsp;&nbsp;&nbsp; U.S.

3.8.2&nbsp;&nbsp;&nbsp; Canada

3.8.3&nbsp;&nbsp;&nbsp; Europe

3.8.4&nbsp;&nbsp;&nbsp; India

3.8.5&nbsp;&nbsp;&nbsp; Japan

3.8.6&nbsp;&nbsp;&nbsp; South Korea

3.8.7&nbsp;&nbsp;&nbsp; Australia

3.8.8&nbsp;&nbsp;&nbsp; Singapore

3.9&nbsp;&nbsp;&nbsp; Reimbursement landscape

3.9.1&nbsp;&nbsp;&nbsp; U.S.

3.9.2&nbsp;&nbsp;&nbsp; Europe

3.9.3&nbsp;&nbsp;&nbsp; Canada

3.9.4&nbsp;&nbsp;&nbsp; Australia

3.9.5&nbsp;&nbsp;&nbsp; New Zealand

3.10&nbsp;&nbsp;&nbsp; U.S. biosimilars insurance coverage, 2022

3.11&nbsp;&nbsp;&nbsp; Biosimilar litigation landscape

3.12&nbsp;&nbsp;&nbsp; Biosimilar product pipeline analysis

3.13&nbsp;&nbsp;&nbsp; Biosimilars approval scenario, 2017-2022

3.13.1&nbsp;&nbsp;&nbsp; U.S.

3.13.2&nbsp;&nbsp;&nbsp; Canada

3.13.3&nbsp;&nbsp;&nbsp; Europe

3.13.4&nbsp;&nbsp;&nbsp; India

3.13.5&nbsp;&nbsp;&nbsp; South Korea

3.13.6&nbsp;&nbsp;&nbsp; Australia

3.13.7&nbsp;&nbsp;&nbsp; New Zealand

3.13.8&nbsp;&nbsp;&nbsp; Singapore

3.13.9&nbsp;&nbsp;&nbsp; Malaysia

3.14&nbsp;&nbsp;&nbsp; Biologics patent expiry scenario

3.15&nbsp;&nbsp;&nbsp; Biosimilars industry evolution

3.16&nbsp;&nbsp;&nbsp; Biosimilars factor analysis

3.16.1&nbsp;&nbsp;&nbsp; Access

3.16.2&nbsp;&nbsp;&nbsp; Regulations

3.16.3&nbsp;&nbsp;&nbsp; Payer assessment and access

3.16.4&nbsp;&nbsp;&nbsp; Physician acceptance

3.16.5&nbsp;&nbsp;&nbsp; Patient acceptance

3.16.6&nbsp;&nbsp;&nbsp; Number of biosimilar approvals

3.17&nbsp;&nbsp;&nbsp; Biosimilars landscape - country analysis

3.17.1&nbsp;&nbsp;&nbsp; U.S.

3.17.2&nbsp;&nbsp;&nbsp; Europe

3.17.3&nbsp;&nbsp;&nbsp; China

3.17.4&nbsp;&nbsp;&nbsp; Japan

3.17.5&nbsp;&nbsp;&nbsp; India

3.17.6&nbsp;&nbsp;&nbsp; South Korea

3.18&nbsp;&nbsp;&nbsp; International policies on use of biosimilar drugs

3.18.1&nbsp;&nbsp;&nbsp; Interchangeability, Switching and Substitution

3.18.2&nbsp;&nbsp;&nbsp; Supply Side Policies

3.18.3&nbsp;&nbsp;&nbsp; Prescribing Incentives

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Strategic outlook matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Biosimilars Market Size and Forecast, By Product (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by product

5.2&nbsp;&nbsp;&nbsp; Recombinant Non-Glycosylated Proteins

5.2.1&nbsp;&nbsp;&nbsp; Human Growth Hormone

5.2.2&nbsp;&nbsp;&nbsp; Granulocyte Colony-Stimulating Factor (Filgrastim)

5.2.3&nbsp;&nbsp;&nbsp; Insulin

5.2.4&nbsp;&nbsp;&nbsp; Interferon

5.2.4.1&nbsp;&nbsp;&nbsp;Alfa

5.2.4.2&nbsp;&nbsp;&nbsp;Beta

5.3&nbsp;&nbsp;&nbsp; Recombinant Glycosylated Proteins

5.3.1&nbsp;&nbsp;&nbsp; Erythropoietin

5.3.1.1&nbsp;&nbsp;&nbsp;Alfa

5.3.1.2&nbsp;&nbsp;&nbsp;Zeta

5.3.2&nbsp;&nbsp;&nbsp; Monoclonal Antibodies

5.3.2.1&nbsp;&nbsp;&nbsp;Infliximab

5.3.2.2&nbsp;&nbsp;&nbsp;Rituximab

5.3.2.3&nbsp;&nbsp;&nbsp;Adalimumab

5.3.2.4&nbsp;&nbsp;&nbsp;Trastuzumab

5.3.2.5&nbsp;&nbsp;&nbsp;Bevacizumab

5.3.2.6&nbsp;&nbsp;&nbsp;Etanercept

5.3.3&nbsp;&nbsp;&nbsp; Follitropin

5.3.3.1&nbsp;&nbsp;&nbsp;Alfa

5.3.3.2&nbsp;&nbsp;&nbsp;Beta

5.3.4&nbsp;&nbsp;&nbsp; Low Molecular Weight Heparin (LMWHs)

Chapter 6&nbsp;&nbsp;&nbsp;Biosimilars Market Size and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Hematology

6.2.1&nbsp;&nbsp;&nbsp; Neutropenia

6.2.2&nbsp;&nbsp;&nbsp; Anemia

6.2.3&nbsp;&nbsp;&nbsp; Other hematology applications

6.3&nbsp;&nbsp;&nbsp; Oncology

6.3.1&nbsp;&nbsp;&nbsp; Lung cancer

6.3.2&nbsp;&nbsp;&nbsp; Brain cancer

6.3.3&nbsp;&nbsp;&nbsp; Breast cancer

6.3.4&nbsp;&nbsp;&nbsp; Cervical cancer

6.3.5&nbsp;&nbsp;&nbsp; Colorectal cancer

6.3.6&nbsp;&nbsp;&nbsp; Leukemia

6.3.6.1&nbsp;&nbsp;&nbsp;Non-Hodgkin Lymphoma (NHL)

6.3.6.2&nbsp;&nbsp;&nbsp;Chronic Lymphocytic Leukemia (CLL)

6.3.6.3&nbsp;&nbsp;&nbsp;Others

6.3.7&nbsp;&nbsp;&nbsp; Other cancers

6.4&nbsp;&nbsp;&nbsp; Autoimmune Disease

6.4.1&nbsp;&nbsp;&nbsp; Arthritis

6.4.1.1&nbsp;&nbsp;&nbsp;Rheumatoid arthritis

6.4.1.2&nbsp;&nbsp;&nbsp;Psoriatic arthritis

6.4.1.3&nbsp;&nbsp;&nbsp;Juvenile arthritis

6.4.1.4&nbsp;&nbsp;&nbsp;Ankylosing spondylitis

6.4.1.5&nbsp;&nbsp;&nbsp;Other arthritis

6.4.2&nbsp;&nbsp;&nbsp; Inflammatory Bowel Disease (IBD)

6.4.2.1&nbsp;&nbsp;&nbsp;Ulcerative Colitis

6.4.2.2&nbsp;&nbsp;&nbsp;Crohn&#39;s disease

6.4.2.3&nbsp;&nbsp;&nbsp;Other IBD

6.4.3&nbsp;&nbsp;&nbsp; Psoriasis

6.4.4&nbsp;&nbsp;&nbsp; Other autoimmune diseases

6.5&nbsp;&nbsp;&nbsp; Growth hormone deficiency

6.6&nbsp;&nbsp;&nbsp; Diabetes

6.7&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Biosimilars Market Size and Forecast, By Manufacturer (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by manufacturer

7.2&nbsp;&nbsp;&nbsp; Contract research and manufacturing services

7.3&nbsp;&nbsp;&nbsp; In-house

Chapter 8&nbsp;&nbsp;&nbsp;Biosimilars Market Size and Forecast, By Technology (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by technology

8.2&nbsp;&nbsp;&nbsp; Recombinant DNA Technology (rDNA technology)

8.3&nbsp;&nbsp;&nbsp; Monoclonal Antibodies (MAb) Technology

Chapter 9&nbsp;&nbsp;&nbsp;Biosimilars Market Size and Forecast, By Region (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Turkey

9.3.7&nbsp;&nbsp;&nbsp; Austria

9.3.8&nbsp;&nbsp;&nbsp; Belgium

9.3.9&nbsp;&nbsp;&nbsp; Bulgaria

9.3.10&nbsp;&nbsp;&nbsp; Czech Republic

9.3.11&nbsp;&nbsp;&nbsp; Denmark

9.3.12&nbsp;&nbsp;&nbsp; Finland

9.3.13&nbsp;&nbsp;&nbsp; Greece

9.3.14&nbsp;&nbsp;&nbsp; Hungary

9.3.15&nbsp;&nbsp;&nbsp; Ireland

9.3.16&nbsp;&nbsp;&nbsp; Netherlands

9.3.17&nbsp;&nbsp;&nbsp; Norway

9.3.18&nbsp;&nbsp;&nbsp; Romania

9.3.19&nbsp;&nbsp;&nbsp; Slovakia

9.3.20&nbsp;&nbsp;&nbsp; Slovenia

9.3.21&nbsp;&nbsp;&nbsp; Sweden

9.3.22&nbsp;&nbsp;&nbsp; Switzerland

9.3.23&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; New Zealand

9.4.7&nbsp;&nbsp;&nbsp; Singapore

9.4.8&nbsp;&nbsp;&nbsp; Malaysia

9.4.9&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Biocon Ltd.

10.2&nbsp;&nbsp;&nbsp; Sandoz

10.3&nbsp;&nbsp;&nbsp; Viatris

10.4&nbsp;&nbsp;&nbsp; Bio-Thera Solutions

10.5&nbsp;&nbsp;&nbsp; Pfizer

10.6&nbsp;&nbsp;&nbsp; Dr. Reddy&rsquo;s Laboratories

10.7&nbsp;&nbsp;&nbsp; Amgen Inc.

10.8&nbsp;&nbsp;&nbsp; Teva Pharmaceuticals

10.9&nbsp;&nbsp;&nbsp; Fresenius Kabi

10.10&nbsp;&nbsp;&nbsp; Coherus Biosciences

10.11&nbsp;&nbsp;&nbsp; Apobiologix

10.12&nbsp;&nbsp;&nbsp; Biocad

10.13&nbsp;&nbsp;&nbsp; Intas Pharma

10.14&nbsp;&nbsp;&nbsp; Reliance Life Sciences

10.15&nbsp;&nbsp;&nbsp; Celltrion

10.16&nbsp;&nbsp;&nbsp; Zydus Cadila

10.17&nbsp;&nbsp;&nbsp; Lupin Pharma

10.18&nbsp;&nbsp;&nbsp; Samsung Bioepis

&nbsp;&nbsp;&nbsp;

Biosimilars Market

Customize This Report

Industries

Information

Link

Global Headquarters